CA2592631A1 - Compositions and methods to treat recurrent medical conditions - Google Patents

Compositions and methods to treat recurrent medical conditions Download PDF

Info

Publication number
CA2592631A1
CA2592631A1 CA002592631A CA2592631A CA2592631A1 CA 2592631 A1 CA2592631 A1 CA 2592631A1 CA 002592631 A CA002592631 A CA 002592631A CA 2592631 A CA2592631 A CA 2592631A CA 2592631 A1 CA2592631 A1 CA 2592631A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmacologic agent
dcs
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002592631A
Other languages
English (en)
French (fr)
Inventor
Jason Mcdevitt
Michael Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2592631A1 publication Critical patent/CA2592631A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002592631A 2003-12-29 2004-12-29 Compositions and methods to treat recurrent medical conditions Abandoned CA2592631A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53300303P 2003-12-29 2003-12-29
US60/533,003 2003-12-29
US62525304P 2004-11-05 2004-11-05
US60/625,253 2004-11-05
PCT/US2004/043628 WO2005065308A2 (en) 2003-12-29 2004-12-29 Compositions and methods to treat recurrent medical conditions

Publications (1)

Publication Number Publication Date
CA2592631A1 true CA2592631A1 (en) 2005-07-21

Family

ID=34752985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002592631A Abandoned CA2592631A1 (en) 2003-12-29 2004-12-29 Compositions and methods to treat recurrent medical conditions

Country Status (8)

Country Link
US (2) US7846913B2 (cg-RX-API-DMAC7.html)
EP (1) EP1703907A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007517049A (cg-RX-API-DMAC7.html)
KR (1) KR20070007276A (cg-RX-API-DMAC7.html)
AU (1) AU2004311869A1 (cg-RX-API-DMAC7.html)
CA (1) CA2592631A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006127475A (cg-RX-API-DMAC7.html)
WO (1) WO2005065308A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
CA2609972C (en) * 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2007018801A1 (en) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
ATE515259T1 (de) * 2007-05-29 2011-07-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit eszopiclon
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
US20100204291A1 (en) * 2009-02-12 2010-08-12 Mcdevitt Jason P Method for Facilitating Extinction Training Using D-Cycloserine
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX336979B (es) * 2011-12-16 2016-02-09 Senosiain S A De C V Lab Combinacion farmaceutica antineuritica y composiciones.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2025173704A1 (ja) * 2024-02-16 2025-08-21 エフバイタル株式会社 薬剤のスクリーニング方法、および剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CA2372073A1 (en) * 1999-04-29 2000-11-09 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycine cleavage system inhibitors as potential antipsychotics
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations

Also Published As

Publication number Publication date
US20050143314A1 (en) 2005-06-30
JP2007517049A (ja) 2007-06-28
US8309535B2 (en) 2012-11-13
KR20070007276A (ko) 2007-01-15
RU2006127475A (ru) 2008-02-10
AU2004311869A1 (en) 2005-07-21
US20110071102A1 (en) 2011-03-24
EP1703907A2 (en) 2006-09-27
US7846913B2 (en) 2010-12-07
WO2005065308A2 (en) 2005-07-21
EP1703907A4 (en) 2009-03-25
WO2005065308A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
US20240148756A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
US20040029941A1 (en) Zonisamide use in obesity and eating disorders
US8703823B2 (en) Methods for treatment of migraine and symptoms thereof
BG65677B1 (bg) Използване на дапоксетин, бързодействащ реактивен серотонинов инхибитор за лечение на сексуална дисфункция
JP2016138142A (ja) 大うつ病を有する患者において減量療法を提供する方法
AU748993B2 (en) Pharmaceutical combinations containing tramadol
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
CN117177741A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
US20110244057A1 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
TW202237103A (zh) 用於治療抑鬱症的nr2b-nmda受體nam之劑量方案
US20070219201A1 (en) Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
TW200821296A (en) Use of sertindole for the preventive treatment of suicidal behaviour
WO2008037045A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
CN1972685A (zh) 治疗复发性的需要治疗的病症的组合物及方法
HK1100840A (en) Compositions and methods to treat recurrent medical conditions
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
WO2002056869A2 (en) Method for treating sexual disorders
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
CHECK et al. 2.72 Atomoxetine
MXPA01001178A (es) Metodos y composiciones para tratamiento y la prevencion de ciertos trastornos psiquiatricos y medicos mediante el empleo de la moclobemida.

Legal Events

Date Code Title Description
FZDE Discontinued